Sep 12, 2025 8:30am EDT FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
Sep 11, 2025 8:30am EDT FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
Sep 10, 2025 8:30am EDT FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
Aug 27, 2025 8:30am EDT FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Jul 31, 2025 4:30pm EDT FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 28, 2025 8:30am EDT FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
Jul 09, 2025 8:30am EDT FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
Jul 07, 2025 4:35pm EDT FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10